S100A9 treatment decreases the secretion of pro-inflammatory cytokines (A) 5 days after LPS injection, sera were collected and tested for IL-6 by ELISA. by Annabelle Cesaro (112070)

Effect of ursodeoxycholic acid (150 mg/kg, p.o.) and fenofibrate (100 mg/kg, p.o.) on aortic malondialdehyde (MDA) content (a) and aortic reduced glutathione (GSH) content (b) in f... by Amr A. A. Mahmoud (627688)

HDAC inhibition by quisinostat synergizes with proteasome inhibition to decrease synovial sarcoma cell viability. by Aimée N. Laporte (3617987)

Subjects:

Phospho-ERK level is decreased in 3D spheroids. by Keven Huang (675616)

“…(<b>C</b>) At 100,000 cells per spheroid, HeyA8 cells treated with SDF-1α and PMA showed activation of phospho-ERK levels. (**, P <0.005 vs Adh, 1-way ANOVA). …”

Diagram of Outdoor Terrains; Participants performed two loops (clockwise and counterclockwise). by Benjamin S. Killen (22766029)

MCF-7 cells were treated with 0, 10, or 20 μM of Peptide 1 or Peptide 2 for 48h. by Deepu Dowarha (5673440)

Subjects:

S100A1 complete sequence indicating highlighted region selected for peptide construction, attaching it to HIV-TAT peptide forming Peptide 1 and its scramble arrangement in Peptide... by Deepu Dowarha (5673440)

Subjects:

Fig 9 - by Deepu Dowarha (5673440)

Subjects:

The p53-MDM2 interaction was monitored via fluorescence spectroscopy. by Deepu Dowarha (5673440)

Subjects:

Analysis of WST-1 assay. by Deepu Dowarha (5673440)

Subjects:

The ¹H−¹⁵N HSQC spectra overlay of free ¹⁵N p53 (1–73) (red) and in complex with unlabelled S100A1 (yellow). by Deepu Dowarha (5673440)

Subjects:

Fig 16 - by Deepu Dowarha (5673440)

Subjects:

Competitive binding experiment. by Deepu Dowarha (5673440)

Subjects:

The MCF-7 and/or MDA-MB-468 cells were treated with or without 10 μM Peptide 1 for 48h. by Deepu Dowarha (5673440)

Subjects:

The p53-Peptide 1 interaction was monitored via fluorescence spectroscopy. by Deepu Dowarha (5673440)

Subjects:

Fig 2 - by David Mathar (9707947)

Subjects:

General conditions and periodontal parameters at baseline and follow-up in the sub-group analysis [moderately poor glycemic control (HbA1c; 7.0 to 10.0%)]. by Hirofumi Mizuno (4597621)

Process steps in the Entscheidungsnavi. by Christian Hannes (17817132)

Homocysteine decreases G9a expression both <i>in vitro</i> and <i>in vivo</i>. by Wenjing Lei (772749)

Hcy decreased the binding of G9a to the <i>COL1A1</i> promoter. by Wenjing Lei (772749)